Opiate analgesics are broadly used throughout the management of pain. However, repeated and long term administration of opiates could be associated with tolerance to opiates restricting their administration (1).
Introduction
Opiate analgesics are broadly used throughout the management of pain. However, repeated and long term administration of opiates could be associated with tolerance to opiates restricting their administration (1) .
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Tolerance, i.e. diminution of the drug efficacy following long-term administration, could be associated with the requirement of augmented analgesic doses in order to obtain anticipated effects (2) . To maintain proper pharmacologic approaches for controlling chronic pain, management of the tolerance process seems inevitable. Chronic opioid treatment leads to activation of N-methyl-D-aspartate (NMDA) receptor and subsequent release and influx of intracellular Ca2+ and activation of protein kinase C (PKC) (3, 4) . Consequently, administration of NMDA receptor antagonists (e.g. ketamine) is known to prolong and enhance the analgesic effects of morphine and prohibit analgesic tolerance (5) (6) (7) (8) . Magnesium is a NMDA channel blocker used in hypomagnesaemia, toxemia of pregnancy, torsade's de pointes dysrhythmias and preterm labor (9, 10) . It can also diminish the tolerance and dependence to the analgesic effects of morphine through blocking Ca2+ channels related to NMDA receptors (11) (12) (13) (14) .
Bupropion, a non-tricyclic antidepressant, is a popular treatment in SSRI's intolerance, or for people wanting to quit smoking. In recent studies, potential use of bupropion in tolerance and dependence has been indicated (15) . Magnesium sulfate and bupropion may have a potential role in the prevention of morphine tolerance. In the present study we investigated the effect of pretreatment of magnesium sulfate, bupropion and co-administration of them in the development of morphine induced tolerance. Induction of tolerance and treatment protocols Animals were divided into nine groups which received drugs intraperitoneally for four consecutive days according to the following protocol: Group 1: saline (10 ml/kg) + saline (10 ml/kg), Group 2: morphine (50 mg/kg) + saline (10 ml/kg), Group 3, 4 and 5: morphine (50 mg/kg) + magnesium sulfate (20, 40 and 60 mg/kg), Group 6, 7 and 8: morphine (50 mg/kg) + bupropion (2, 4 and 8 mg/kg) and Group 9: morphine (50 mg/kg) + magnesium sulfate (20 mg/kg) + bupropion (2 mg/kg). To evaluate the degree of tolerance in each group, a test dose of morphine (9 mg/kg) was administered 24 hours after the last dose of morphine. In the hot-plate test, thermal stimulation was measured at time intervals of 0, 15, 30, 45 and 60 minutes.
Materials and methods
Drugs
Hot-plate test
Hot plate is a widely used test to assess nociception. Each mice was placed on a surface (23×23 cm) maintained at 52±0.5oC surrounded by a plexiglass wall with 20 cm height. Hot-plate latency was recorded when the animal licked its hind paw. A cut-off time (40 sec) was imposed to prevent tissue damage. Hot-plate response latency results were expressed as the percentage of Maximal 
Statistical analysis
Statistical analysis of each data set was performed by SPSS software (version 17). All results were presented as mean±SEM for eight rats. Statistical comparisons among the experimental groups were made by one way analysis of variance (ANOVA) followed by Tukey post-hoc test where differences with p values less that 0.05 were considered significant.
Results
Development of morphine induced tolerance to analgesic effects
In both groups of saline and morphine, antinociceptive responses of a test dose of morphine (9 mg/kg, IP) was assayed 24 h after the last dose of morphine (50 mg/kg, IP) and saline injection in morphine and saline receiving groups, respectively. Animals that became tolerant to morphine exhibited only a small anti-nociceptive effect. Compared to saline group, morphine receiving group showed lesser MPE % due to developed tolerance (Fig.  1 ).
Figure 1:
Effects of morphine on tolerant and non-tolerant mice. Saline group received saline (10 ml/kg, ip) + saline (10 ml/kg, ip) for 4 days and morphine receiving group treated by morphine (Mor, 50 mg/kg, ip) + saline (10 ml/kg, ip) for 4 days. Results are expressed as Mean ± SEM for eight rats in each group. ***P<0.001, significantly different from the control group (Saline + Saline).
Effects of administration of magnesium sulfate on morphine induced tolerance As it is shown in Figure 2 , magnesium sulfate injection (20, 40 and 60 mg/kg, IP) 30 min before daily morphine administration, decreased significantly the tolerance to the analgesic effects of morphine in a dose dependently manner. The best result was achieved in dose of 60 mg/kg of magnesium sulfate which was more significant at the time of 30 and 45 min. Effects of administration of bupropion on morphine induced tolerance Administration of bupropion reduced the tolerance to the morphine (Fig. 3) and the maximum preventative effect on tolerance was observed at the time 30 and 45 min. Similar to magnesium, the higher dose of bupropion (8 mg/kg) was found to be the best dose for morphine induced tolerance prevention. 
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Effects of co-administration of magnesium sulfate and bupropion on morphine induced tolerance Fig. 4 illustrates the preventative effects of coadministration of magnesium sulfate (20 mg/kg, IP) and bupropion (2 mg/kg, IP) on morphine induced tolerance. As shown, the combination therapy had synergic effects on the prevention of morphine induced tolerance and this difference in tolerance level was higher compared to the both of the single injection of drugs in all time intervals. In other words, the combination of low dose of each drug exhibited more effective results in comparison even with the high dose of each drug in single administration. 
Discussion
Opioid tolerance is a complex event mediated by diverse behavioral and cellular adaptations. Recent studies propose that repeated administration of opiate enhance activation of NMDA-receptors through G protein associated opioid receptors (16, 17) . The responsible mechanism is through opioid-mediated PKC activation which removes magnesium blockade of NMDA receptors and the final effect is NMDA receptors activation. Following NMDA activation as a positive feedback, additional PKC translocation and activation is stimulated which eventually result in hyperalgesia and opioid tolerance (18) (19) (20) (21) . This opiate related activation of NMDA-receptors initiates intracellular changes such as influx of Ca2+ and subsequent production of nitric oxide (NO) and increase in cGMP level, which all have been shown to contribute critically to the opioid tolerance development (22, 23) . NO is able to further increase excitotoxicity by enhancing glutamate release from presynaptic neurons and inhibiting glial glutamate transporters (24) (25) (26) (27) (28) (29) . Although the exact mechanism of tolerance development is not well-understood, some mechanisms such as norepinephrine dopamine reuptake inhibition and also glutamate release inhibition have been reported to play role (30) .
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Glutamatergic activation of NMDA receptors is involved in morphine tolerance, and the blockade of this system by different NMDA receptor antagonists, such as MK-801 and ketamine has been reported (31) (32) (33) (34) (35) (36) . Based on these evidences and according to the results of this study, the efficacy of bupropion and magnesium sulfate in reducing morphine induced tolerance is demonstrated. Investigations by Lin et al. resulted in a dosedependent inhibition of 4-aminopyridine (4-AP)-evoked release of glutamate by suppressing voltage-dependent Ca2+ channel and MEK/ERK activity of bupropion (37) (38) (39) (40) . Therefore, through this inhibitory effect of bupropion on glutamate level, the affection on NMDA receptors is mediated and it can be considered as the responsible mechanism of effectiveness of bupropion on tolerance process. In addition, the property of dopamine and norepinephrine reuptake inhibitory of bupropion may have a role in preventing tolerance phenomena emergence. That NMDA receptors are generally blocked by magnesium at the resting membrane potentials is well-known. Chronic administration of opiate could be associated with antagonization of magnesium blockade of NMDA receptors followed by opening of the Ca2+ channels and increase in intracellular Ca2+ concentrations (41) (42) (43) . Interestingly, this could be reversed by administration of magnesium; the mechanism behind this phenomenon is the potency of magnesium in blocking the Ca2+ channel of NMDA receptors (44) . This, however, is not limited to the above-mentioned mechanism and the following mechanisms have also been identified: decreasing presynaptic release of catecholamines especially dopamine, glutamate effect on NMDA receptors in the brain and direct action of Mg2+ on serotonin receptors (45) (46) (47) . Considering all these roles of magnesium sulfate and bupropion and the neurobiology of tolerance phenomena, the basis of coadministration of these drugs can be explained and supported by the results obtained from this study.
Furthermore, combination of magnesium and bupropion is of further effective analgesic properties than either compound alone. This might be imputed to different and multiple effects of these drugs in tolerance inducing pathway which result in acting in a super-additive manner.
Conclusion
Low doses of bupropion (2mg/kg, IP) in combination with a low dose of magnesium (20 mg/kg, IP) decreases the development of morphine tolerance. Increased efficacy of morphine, especially in the treatment for chronic pain, could be achieved through pharmacological manipulation of NMDA receptor activity.
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